Full Characterization Of Enoxaparin Necessary For ANDA Approval, Momenta Says
This article was originally published in The Pink Sheet Daily
Executive Summary
Momenta maintains that unless Amphastar and Teva can fully characterize enoxaparin, their generic versions of Aventis' Lovenox will not receive approval